{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:21:15Z","timestamp":1789881675465,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou Third People\u2019s Hospital","award":["Key Talents Project"],"award-info":[{"award-number":["Key Talents Project"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr J"],"DOI":"10.1186\/s12937-025-01081-0","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T01:28:58Z","timestamp":1736818138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States"],"prefix":"10.1186","volume":"24","author":[{"given":"Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longgen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"1081_CR1","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","DOI":"10.3350\/cmh.2024.0431"},{"key":"1081_CR2","doi-asserted-by":"publisher","unstructured":"Tesfai K, Pace J, El-Newihi N, Martinez ME, Tincopa M, Loomba R. Disparities for Hispanic adults with metabolic dysfunction-associated steatotic liver disease in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.06.038.","DOI":"10.1016\/j.cgh.2024.06.038"},{"issue":"3","key":"1081_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023;32(3):197\u2013213.","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"1081_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356.","journal-title":"J Hepatol"},{"issue":"1","key":"1081_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nyas.15184","volume":"1538","author":"W Fan","year":"2024","unstructured":"Fan W, Bradford TM, T\u00f6r\u00f6k NJ. Metabolic dysfunction-associated liver disease and diabetes: matrix remodeling, fibrosis, and therapeutic implications. Ann N Y Acad Sci. 2024;1538(1):21\u201333.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"1081_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-024-02343-7","volume":"23","author":"Q Chen","year":"2024","unstructured":"Chen Q, Hu P, Hou X, Sun Y, Jiao M, Peng L, et al. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol. 2024;23(1):232.","journal-title":"Cardiovasc Diabetol"},{"key":"1081_CR7","doi-asserted-by":"crossref","unstructured":"Riley DR, Hydes T, Hernadez G, Zhao SS, Alam U, Cuthbertson DJ. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int. 2024;44(10):2538\u201350.","DOI":"10.1111\/liv.16016"},{"issue":"11","key":"1081_CR8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","volume":"10","author":"GA Michelotti","year":"2013","unstructured":"Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656\u201365.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"1081_CR9","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364.","journal-title":"Cell"},{"issue":"10","key":"1081_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","volume":"9","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9(10):944\u201356.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1081_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4254\/wjh.v16.i6.871","volume":"16","author":"R Wong","year":"2024","unstructured":"Wong R, Yuan LY. Sarcopenia and metabolic dysfunction associated steatotic liver disease: time to address both. World J Hepatol. 2024;16(6):871\u20137.","journal-title":"World J Hepatol"},{"issue":"6","key":"1081_CR12","doi-asserted-by":"publisher","first-page":"101544","DOI":"10.1016\/j.aohep.2024.101544","volume":"29","author":"A Malik","year":"2024","unstructured":"Malik A, Javaid S, Malik MI, Qureshi S. Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Ann Hepatol. 2024;29(6):101544.","journal-title":"Ann Hepatol"},{"issue":"9","key":"1081_CR13","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","volume":"43","author":"X Li","year":"2024","unstructured":"Li X, He J, Sun Q. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Clin Nutr. 2024;43(9):2005\u201316.","journal-title":"Clin Nutr"},{"issue":"1","key":"1081_CR14","doi-asserted-by":"publisher","first-page":"91100","DOI":"10.4291\/wjgp.v15.i1.91100","volume":"15","author":"S Giri","year":"2024","unstructured":"Giri S, Anirvan P, Angadi S, Singh A, Lavekar A. Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2024;15(1):91100.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"9","key":"1081_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/MEG.0000000000001397","volume":"31","author":"K Wijarnpreecha","year":"2019","unstructured":"Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur J Gastroenterol Hepatol. 2019;31(9):1121\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"1081_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/liv.14719","volume":"41","author":"YC Hsieh","year":"2021","unstructured":"Hsieh YC, Joo SK, Koo BK, Lin HC, Kim W. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2021;41(3):494\u2013504.","journal-title":"Liver Int"},{"issue":"14","key":"1081_CR17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3390\/nu16142220","volume":"16","author":"M Beygi","year":"2024","unstructured":"Beygi M, Ahi S, Zolghadri S, Stanek A. Management of metabolic-associated fatty liver disease\/metabolic dysfunction-associated steatotic liver disease: from medication therapy to nutritional interventions. Nutrients. 2024;16(14):2220.","journal-title":"Nutrients."},{"issue":"15","key":"1081_CR18","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/nu16152532","volume":"16","author":"K Yang","year":"2024","unstructured":"Yang K, Chung BS, Ryu T. Impact of physical activity on overall survival and liver cirrhosis incidence in steatotic liver disease: insights from a large cohort study using inverse probability of treatment weighting. Nutrients. 2024;16(15):2532.","journal-title":"Nutrients"},{"issue":"2","key":"1081_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ueg2.12524","volume":"12","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Hegmar H, Moreno C. Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease. United Eur Gastroenterol J. 2024;12(2):168\u201376.","journal-title":"United Eur Gastroenterol J"},{"issue":"16","key":"1081_CR20","doi-asserted-by":"publisher","first-page":"8641","DOI":"10.3390\/ijms25168641","volume":"25","author":"A Banerjee","year":"2024","unstructured":"Banerjee A, Farci P. Fibrosis and Hepatocarcinogenesis: Role of Gene-Environment Interactions in Liver Disease Progression. Int J Mol Sci. 2024;25(16):8641.","journal-title":"Int J Mol Sci."},{"key":"1081_CR21","doi-asserted-by":"publisher","first-page":"101547","DOI":"10.1016\/j.eclinm.2022.101547","volume":"51","author":"YT Cao","year":"2022","unstructured":"Cao YT, Xiang LL, Qi F, Zhang YJ, Chen Y, Zhou XQ. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. EClinicalMedicine. 2022;51:101547.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"1081_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/gerona\/glu010","volume":"69","author":"SA Studenski","year":"2014","unstructured":"Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547\u201358.","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"4","key":"1081_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/apt.13889","volume":"45","author":"S Petta","year":"2017","unstructured":"Petta S, Ciminnisi S, Di Marco V, Cabibi D, Camm\u00e0 C, Licata A, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;45(4):510\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1081_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","volume":"66","author":"BK Koo","year":"2017","unstructured":"Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66(1):123\u201331.","journal-title":"J Hepatol"},{"issue":"9","key":"1081_CR25","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/jgh.14607","volume":"34","author":"MK Kang","year":"2019","unstructured":"Kang MK, Park JG, Lee HJ, Kim MC. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019;34(9):1633\u201340.","journal-title":"J Gastroenterol Hepatol"},{"key":"1081_CR26","doi-asserted-by":"publisher","first-page":"883015","DOI":"10.3389\/fnut.2022.883015","volume":"9","author":"W Guo","year":"2022","unstructured":"Guo W, Zhao X, Miao M, Liang X, Li X, Qin P, et al. Association between skeletal muscle mass and severity of steatosis and fibrosis in non-alcoholic fatty liver disease. Front Nutr. 2022;9:883015.","journal-title":"Front Nutr"},{"issue":"Suppl","key":"1081_CR27","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.3350\/cmh.2022.0358","volume":"29","author":"SK Joo","year":"2023","unstructured":"Joo SK, Kim W. Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S68-78.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"1081_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13098-023-01022-z","volume":"15","author":"ZJ Liu","year":"2023","unstructured":"Liu ZJ, Zhu CF. Causal relationship between insulin resistance and sarcopenia. Diabetol Metab Syndr. 2023;15(1):46.","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"1081_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1172\/JCI34275","volume":"118","author":"C Postic","year":"2008","unstructured":"Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829\u201338.","journal-title":"J Clin Invest"},{"issue":"12","key":"1081_CR30","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1210\/jc.2006-0587","volume":"91","author":"KM Utzschneider","year":"2006","unstructured":"Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91(12):4753\u201361.","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"1081_CR31","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/jcsm.12598","volume":"11","author":"S Kang","year":"2020","unstructured":"Kang S, Moon MK, Kim W, Koo BK. Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey. J Cachexia Sarcopenia Muscle. 2020;11(5):1232\u201341.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8","key":"1081_CR32","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","volume":"22","author":"Y Sakurai","year":"2021","unstructured":"Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1081_CR33","doi-asserted-by":"publisher","first-page":"e10805","DOI":"10.1371\/journal.pone.0010805","volume":"5","author":"P Srikanthan","year":"2010","unstructured":"Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS ONE. 2010;5(5):e10805.","journal-title":"PLoS ONE"},{"issue":"1","key":"1081_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/MCO.0b013e32834dd297","volume":"15","author":"I Beyer","year":"2012","unstructured":"Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care. 2012;15(1):12\u201322.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"2","key":"1081_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3350\/cmh.2021.0082","volume":"28","author":"JW Han","year":"2022","unstructured":"Han JW, Kim DI, Nam HC, Chang UI, Yang JM, Song DS. Association between serum tumor necrosis factor-\u03b1 and sarcopenia in liver cirrhosis. Clin Mol Hepatol. 2022;28(2):219\u201331.","journal-title":"Clin Mol Hepatol"},{"key":"1081_CR36","doi-asserted-by":"publisher","first-page":"9547613","DOI":"10.1155\/2018\/9547613","volume":"2018","author":"M Masarone","year":"2018","unstructured":"Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:9547613.","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"1081_CR37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.14218\/JCTH.2022.00067","volume":"10","author":"K Clare","year":"2022","unstructured":"Clare K, Dillon JF, Brennan PN. Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD. J Clin Transl Hepatol. 2022;10(5):939\u201346.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"1081_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11010-022-04506-0","volume":"478","author":"XJ Wu","year":"2023","unstructured":"Wu XJ, Xie Y, Gu XX, Zhu HY, Huang LX. LncRNA XIST promotes mitochondrial dysfunction of hepatocytes to aggravate hepatic fibrogenesis via miR-539-3p\/ADAMTS5 axis. Mol Cell Biochem. 2023;478(2):291\u2013303.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"1081_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/MCG.0b013e3181ec5c66","volume":"45","author":"SA Polyzos","year":"2011","unstructured":"Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol. 2011;45(1):50\u20134.","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"1081_CR40","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","volume":"65","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1062\u201379.","journal-title":"Metabolism"},{"issue":"3","key":"1081_CR41","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1053\/j.gastro.2006.05.054","volume":"131","author":"H Tilg","year":"2006","unstructured":"Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131(3):934\u201345.","journal-title":"Gastroenterology"},{"issue":"6","key":"1081_CR42","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/j.1572-0241.2007.01774.x","volume":"103","author":"A Wieckowska","year":"2008","unstructured":"Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103(6):1372\u20139.","journal-title":"Am J Gastroenterol"}],"container-title":["Nutrition Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12937-025-01081-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12937-025-01081-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12937-025-01081-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T01:29:07Z","timestamp":1736818147000},"score":1,"resource":{"primary":{"URL":"https:\/\/nutritionj.biomedcentral.com\/articles\/10.1186\/s12937-025-01081-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1186\/s12937-025-01081-0","relation":{},"ISSN":["1475-2891"],"issn-type":[{"value":"1475-2891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans in US cohort were approved by the National Center for Health Statistics Ethics Review Board. The participants provided their written informed consent to participate in this study. Accordingly, the Changzhou Third People\u2019s Hospital Ethics Committee has determined that no further ethical review approval is required to use NHANES data in this study. The Changzhou Third People\u2019s Hospital Ethics Committee approved the Chinese cohort study (No. 02A-A20230023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}